The results showed that serum RBP4 levels was higher in NAFLD patients than non-NAFLD (SMD 0.28; 95% CI: 0.11–0.46, I2: 89.8%, P = 0.001) (Fig. 2). Here, RBP4 is linked to metabolic dysfunction-associated steatotic liver disease.